28th Annual International Congress on Hematologic Malignancies 2024

28th year, the International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides practitioners who manage hematologic malignancies with the practical tools.

To translate emerging data into the best therapy for their patients, to personalize care according to patient and tumor characteristics, and to apply novel treatment strategies to improve patient outcomes.

We will continue to spotlight advances in CAR T-cell therapy, along with the expanding array of bispecific agents and antibody-drug conjugates for hematologic malignancies. Additionally, core sessions will continue to focus on methods to apply state-of-the-art treatment strategies in your clinical practice setting.

This engaging and highly interactive meeting will provide ample opportunity for attendees to interact with internationally renowned experts in the management of leukemias, lymphomas, myeloma, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), and benign hematologic malignancies. Our faculty will distill practice-changing evidence and recommend how to put this information into clinical context, so that you may apply the latest evidence to real-world patient-care scenarios. Proactive measures to mitigate and manage treatment-related toxicities associated with new cellular therapies will also be discussed.